Evommune EVMN
NYSE EVMN
$5.18 -0.20 (-3.72%)
As of: Oct 21, 2026 · 3:59 PM EDT

Evommune (EVMN) Long-Term Debt Repayments (2024 - 2026)

Updated

Evommune (EVMN) recorded Long-Term Debt Repayments of $129,000 in Q2 2026, up 40.2% from $92,000 a year earlier and up 29.0% from the prior quarter.

Analysis

Evommune (EVMN) Long-Term Debt Repayments (2024 - 2026) Analysis & Trends

On a TTM basis, Evommune's Long-Term Debt Repayments came in at $437,000 as of Jun 30, 2026; for FY2025, it was $400,000, up 92.3% from FY2024.

  • Across earlier years, Long-Term Debt Repayments came in at $208,000 in FY2024.
  • Per Business Quant, the preceding three quarters came in at $100,000 (Q1 2026), $100,000 (Q4 2025) and $108,000 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Repayment (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 873.00 Mn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 1.00 Mn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 2.00 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 5.00 Mn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 20.00 Mn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 2.46 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn -
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 17.00 Mn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -
10 Evommune 186.46 Mn -451.06 Mn - 129,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 129,000.00
Mar 31, 2026 100,000.00
Dec 31, 2025 -58,000.00
Sep 30, 2025 266,000.00
Jun 30, 2025 92,000.00
Mar 31, 2025 100,000.00
Dec 31, 2024 -76,000.00
API Access

Evommune Long-Term Debt Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=EVMN&period=max&api_key=YOUR_API_KEY